8-K: Penumbra Inc. Reports 14.5% Revenue Growth in Q2 2024, Adjusts Full-Year Outlook

Penumbra, Inc. announced a 14.5% increase in revenue for the second quarter of 2024, alongside a revised full-year revenue guidance.

Summary

• Penumbra, Inc. reported a revenue of $299.4 million for the second quarter of 2024, marking a 14.5% increase compared to the same period in 2023.
• The company's U.S. thrombectomy revenue saw a significant rise of 24.9%, reaching $153.7 million.
• A loss from operations of $81.0 million was reported, which includes $110.3 million in one-time non-cash impairment and inventory write-down charges related to its Immersive Healthcare assets.
• Non-GAAP income from operations was $31.7 million for the quarter.
• Adjusted EBITDA reached $46.3 million, with an adjusted EBITDA margin of 15.5%.
• Cash and marketable investments increased by $26.2 million during the quarter.
• The company has updated its full-year 2024 revenue guidance to $1.18 billion to $1.20 billion, a reduction of $60 million at the midpoint from previous guidance.
• This reduction is attributed to a $20 million decrease in China, $15 million from European business delays, $5 million from Immersive Healthcare, and $20 million from U.S. thrombectomy growth.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the reduced revenue guidance and loss from operations, offset by strong growth in thrombectomy and positive EBITDA. The one-time charges and delays are concerning.

Positives

• Total revenue increased by 14.5% year-over-year, reaching $299.4 million.
• U.S. thrombectomy revenue saw a substantial increase of 24.9%.
• Global thrombectomy product sales grew by 25.2%.
• Adjusted EBITDA was $46.3 million, with a margin of 15.5%.
• Cash and marketable investments increased by $26.2 million in the second quarter.
• The company anticipates non-GAAP gross margin expansion of 100 to 150 basis points in 2024.
• Non-GAAP operating margin expansion of 100-200 basis points is expected in 2024.

Negatives

• The company reported a loss from operations of $81.0 million, including $110.3 million in one-time charges.
• Global embolization and access product sales decreased by 3.1%.
• International embolization and access product sales declined by 10.8%.
• Full-year 2024 revenue guidance has been reduced by $60 million at the midpoint.
• The company is experiencing a $20 million reduction in China due to a challenging economic backdrop.
• There is a $15 million impact from delays in European product launches.

Risks

• The company faces challenges in the Chinese market due to a difficult economic environment for medical devices.
• Delays in the launch of FLASH and BOLT 7 CAVT products in Europe are impacting revenue.
• The strategic move away from the Immersive Healthcare business has resulted in a $5 million revenue reduction.
• The company has reduced its full-year guidance for U.S. thrombectomy growth.
• The company's business and operations are subject to a variety of risks and uncertainties that could cause actual results to differ from projections.

Future Outlook

The company has updated its full-year 2024 revenue guidance to $1.18 billion to $1.20 billion, a reduction of $60 million at the midpoint from previous guidance. They expect non-GAAP gross margin expansion of 100 to 150 basis points and non-GAAP operating margin expansion of 100-200 basis points in 2024.

Management Comments

• Management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business.
• Management considers the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations.
• Management considers non-GAAP gross profit and non-GAAP gross margin useful metrics to investors as they eliminate the impact of non-cash inventory charges related to the impairment of our immersive healthcare asset group.

Industry Context

Penumbra's results reflect the broader trends in the medical device industry, including the impact of economic conditions on sales in China and the challenges of launching new products in international markets. The company's focus on thrombectomy products aligns with the growing demand for minimally invasive procedures.

Comparison to Industry Standards

• Penumbra's 14.5% revenue growth is solid compared to some of its peers in the medical device industry, but the reduction in full-year guidance is a concern.
• Companies like Stryker and Medtronic, which also operate in the neurovascular space, have reported varying growth rates, with some experiencing similar challenges in international markets.
• The 24.9% growth in U.S. thrombectomy revenue is a strong performance, indicating a competitive advantage in this specific market segment.
• The one-time impairment charges related to the Immersive Healthcare business are not uncommon in the industry, as companies often need to adjust their strategies and asset valuations.
• The adjusted EBITDA margin of 15.5% is within the range of profitability for medical device companies, but the company needs to improve its overall profitability to meet investor expectations.

Stakeholder Impact

• Shareholders may be concerned about the reduced revenue guidance and loss from operations.
• Employees may be affected by the strategic shift away from the Immersive Healthcare business.
• Customers may experience delays in the availability of new products in Europe.
• Suppliers may be impacted by changes in the company's production plans.
• Creditors may be concerned about the company's profitability and cash flow.

Next Steps

• Penumbra, Inc. will host a conference call to discuss the second quarter 2024 financial results on July 30, 2024 at 4:30 PM Eastern Time.
• The company will focus on improving its profitability and managing the impact of the Immersive Healthcare business impairment.
• The company will work to mitigate the impact of delays in European product launches.

Key Dates

Keywords

Penumbra, thrombectomy, revenue, EBITDA, medical devices, financial results, healthcare, Immersive Healthcare, guidance, non-GAAP